Journal of Clinical Oncology, Vol 14, 2959-2967, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors

LB Saltz, J Kanowitz, NE Kemeny, L Schaaf, D Spriggs, BA Staton, R Berkery, C Steger, M Eng, A Dietz, P Locker and DP Kelsen
Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. SALTZL@MSKCC.ORG

PURPOSE: To determine the maximum-tolerable dose (MTD) of fluorouracil (5FU) when given with fixed doses of leucovorin and irinotecan (CPT- 11), to define the dose-limiting toxicities of this combination, and to evaluate the effect of 5FU on the pharmacokinetics of CPT-11. PATIENTS AND METHODS: CPT-11, leucovorin, and 5FU were administered in repeated 6-week cycles that consisted of weekly treatment with all three drugs for 4 consecutive weeks followed by a 2-week break. On day 1 of treatment, CPT-11 alone was given by 90-minute infusion, and pharmacokinetic sampling was performed over 24 hours. Leucovorin and 5FU were administered by brief intravenous injection on day 2. On days 8, 15, and 22, CPT-11 infusion was immediately followed by leucovorin and then 5FU. A second 24-hour pharmacokinetic sampling was performed on day 8, which permitted comparison of the pharmacokinetics of CPT-11 with and without 5FU. For the second 6-week cycle, leucovorin was administered first, followed by 5FU and then CPT-11, and a third pharmacokinetic sampling was performed. RESULTS: Forty-two patients were entered onto this trial. The CPT-11 dose was initially fixed at 100 mg/m2. Leucovorin was fixed at 20 mg/m2. 5FU doses of 210, 265, 340, 425, and 500 mg/m2 were studied. When the 500-mg/m2 dose of 5FU was found to be tolerable, this was then maintained and CPT-11 was escalated to 125 and then 150 mg/m2. This final CPT-11 dose exceeded the MTD. Neutropenia was the major dose-limiting toxicity. Diarrhea was common, but was rarely dose-limiting. Coadministration of 5FU had no substantial effect on the pharmacokinetics of CPT-11 or SN-38. Among the 38 patients with colorectal cancer, six partial responses (PRs) were seen in this predominantly 5FU-refractory patient population. CONCLUSION: 5FU does not substantially affect the metabolism of CPT-11 to its active metabolite, SN-38. The combination of CPT-11125 mg/m2, 5FU 500 mg/m2, and leucovorin 20 mg/m2 is feasible and tolerable on this schedule.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S.-G. Kim, S. Y. Oh, H.-C. Kwon, S. Lee, J. H. Kim, S.-H. Kim, and H.-J. Kim A Phase II Study of Irinotecan with Bi-weekly, Low-dose Leucovorin and Bolus and Continuous Infusion 5-fluorouracil (Modified FOLFIRI) as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer Jpn. J. Clin. Oncol., October 8, 2007; (2007) hym103v1. [Abstract] [Full Text] [PDF]

				M. Michael, M. Thompson, R. J. Hicks, P. L. Mitchell, A. Ellis, A. D. Milner, J. Di Iulio, A. M. Scott, V. Gurtler, J. M. Hoskins, et al. Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination J. Clin. Oncol., September 10, 2006; 24(26): 4228 - 4235. [Abstract] [Full Text] [PDF]

				G. Toffoli, E. Cecchin, G. Corona, A. Russo, A. Buonadonna, M. D'Andrea, L. M. Pasetto, S. Pessa, D. Errante, V. De Pangher, et al. The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer J. Clin. Oncol., July 1, 2006; 24(19): 3061 - 3068. [Abstract] [Full Text] [PDF]

				Y. Yamada, A. Ohtsu, N. Boku, Y. Miyata, Y. Shimada, T. Doi, K. Muro, M. Muto, T. Hamaguchi, K. Mera, et al. Phase I/II Study of Oxaliplatin with Weekly Bolus Fluorouracil and High-Dose Leucovorin (ROX) As First-Line Therapy for Patients with Colorectal Cancer. Jpn. J. Clin. Oncol., April 1, 2006; 36(4): 218 - 223. [Abstract] [Full Text] [PDF]

				E. Cecchin, G. Corona, S. Masier, P. Biason, G. Cattarossi, S. Frustaci, A. Buonadonna, A. Colussi, and G. Toffoli Carboxylesterase Isoform 2 mRNA Expression in Peripheral Blood Mononuclear Cells Is a Predictive Marker of the Irinotecan to SN38 Activation Step in Colorectal Cancer Patients Clin. Cancer Res., October 1, 2005; 11(19): 6901 - 6907. [Abstract] [Full Text] [PDF]

				H. I. Hurwitz, L. Fehrenbacher, J. D. Hainsworth, W. Heim, J. Berlin, E. Holmgren, J. Hambleton, W. F. Novotny, and F. Kabbinavar Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer J. Clin. Oncol., May 20, 2005; 23(15): 3502 - 3508. [Abstract] [Full Text] [PDF]

				E. Aranda, A. Carrato, A. Cervantes, J. Sastre, M. A. Gomez, A. Abad, B. Masutti, F. Ribera, E. Marcuello, L. Pronk, et al. Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer Ann. Onc., April 1, 2004; 15(4): 559 - 567. [Abstract] [Full Text] [PDF]

				M. D. Prados, W.K.A. Yung, K. A. Jaeckle, H. I. Robins, M. P. Mehta, H. A. Fine, P. Y. Wen, T. F. Cloughesy, S. M. Chang, M. K. Nicholas, et al. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study Neuro-oncol, January 1, 2004; 6(1): 44 - 54. [Abstract] [PDF]

				L. Villeneuve, H. Girard, L.-C. Fortier, J.-F. Gagne, and C. Guillemette Novel Functional Polymorphisms in the UGT1A7 and UGT1A9 Glucuronidating Enzymes in Caucasian and African-American Subjects and Their Impact on the Metabolism of 7-Ethyl-10-hydroxycamptothecin and Flavopiridol Anticancer Drugs J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 117 - 128. [Abstract] [Full Text] [PDF]

				K. Bouzid, S. Khalfallah, J. Tujakowski, B. Piko, G. Purkalne, S. Plate, P. Padrik, M. Serafy, E. M. Pshevloutsky, and B. Boussard A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer Ann. Onc., July 1, 2003; 14(7): 1106 - 1114. [Abstract] [Full Text] [PDF]

				A. Ohtsu, N. Boku, T. Yoshioka, I. Hyodo, K. Shirao, Y. Shimada, S. Saitoh, A. Nakamura, N. Yamamichi, S. Yamamoto, et al. A Phase II Study of Irinotecan in Combination with 120-h Infusion of 5-Fluorouracil in Patients with Metastatic Colorectal Carcinoma: Japan Clinical Oncology Group Study (JCOG9703) Jpn. J. Clin. Oncol., January 1, 2003; 33(1): 28 - 32. [Abstract] [Full Text] [PDF]

				R. M. Goldberg, S. H. Kaufmann, P. Atherton, J. A. Sloan, A. A. Adjei, H. C. Pitot, S. R. Alberts, J. Rubin, L. L. Miller, and C. Erlichman A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin Ann. Onc., October 1, 2002; 13(10): 1674 - 1680. [Abstract] [Full Text] [PDF]

				A. Falcone, A. Di Paolo, G. Masi, G. Allegrini, R. Danesi, M. Lencioni, E. Pfanner, S. Comis, M. Del Tacca, and P. Conte Sequence Effect of Irinotecan and Fluorouracil Treatment on Pharmacokinetics and Toxicity in Chemotherapy-Naive Metastatic Colorectal Cancer Patients J. Clin. Oncol., August 1, 2001; 19(15): 3456 - 3462. [Abstract] [Full Text] [PDF]

				M. A. Shah and G. K. Schwartz Cell Cycle-mediated Drug Resistance: An Emerging Concept in Cancer Therapy Clin. Cancer Res., August 1, 2001; 7(8): 2168 - 2181. [Abstract] [Full Text] [PDF]

				R. H. J. Mathijssen, R. J. van Alphen, J. Verweij, W. J. Loos, K. Nooter, G. Stoter, and A. Sparreboom Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11) Clin. Cancer Res., August 1, 2001; 7(8): 2182 - 2194. [Abstract] [Full Text] [PDF]

				N. Kemeny, M. Gonen, D. Sullivan, L. Schwartz, F. Benedetti, L. Saltz, J. Stockman, Y. Fong, W. Jarnagin, J. Bertino, et al. Phase I Study of Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic Irinotecan for Unresectable Hepatic Metastases From Colorectal Cancer J. Clin. Oncol., May 15, 2001; 19(10): 2687 - 2695. [Abstract] [Full Text] [PDF]

				U. Vanhoefer, A. Harstrick, W. Achterrath, S. Cao, S. Seeber, and Y. M. Rustum Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview J. Clin. Oncol., March 1, 2001; 19(5): 1501 - 1518. [Abstract] [Full Text] [PDF]

				L. B. Saltz, J. V. Cox, C. Blanke, L. S. Rosen, L. Fehrenbacher, M. J. Moore, J. A. Maroun, S. P. Ackland, P. K. Locker, N. Pirotta, et al. Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer N. Engl. J. Med., September 28, 2000; 343(13): 905 - 914. [Abstract] [Full Text] [PDF]

				S. Cao and Y. M. Rustum Synergistic Antitumor Activity of Irinotecan in Combination with 5-Fluorouracil in Rats Bearing Advanced Colorectal Cancer: Role of Drug Sequence and Dose Cancer Res., July 1, 2000; 60(14): 3717 - 3721. [Abstract] [Full Text]

				H. C. Pitot, R. M. Goldberg, J. M. Reid, J. A. Sloan, P. A. Skaff, C. Erlichman, J. Rubin, P. A. Burch, A. A. Adjei, S. A. Alberts, et al. Phase I Dose-finding and Pharmacokinetic Trial of Irinotecan Hydrochloride (CPT-11) Using a Once-Every-Three-Week Dosing Schedule for Patients with Advanced Solid Tumor Malignancy Clin. Cancer Res., June 1, 2000; 6(6): 2236 - 2244. [Abstract] [Full Text]

				R. F. DeVore, D. H. Johnson, J. Crawford, J. Garst, I. W. Dimery, J. Eckardt, S. G. Eckhardt, G. L. Elfring, L. J. Schaaf, C. K. Hanover, et al. Phase II Study of Irinotecan Plus Cisplatin in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., September 1, 1999; 17(9): 2710 - 2710. [Abstract] [Full Text] [PDF]

				M. Ducreux, M. Ychou, J.-F. Seitz, M. Bonnay, A. Bexon, J.-P. Armand, M. Mahjoubi, D. Mery-Mignard, and P. Rougier Irinotecan Combined With Bolus Fluorouracil, Continuous Infusion Fluorouracil, and High-Dose Leucovorin Every Two Weeks (LV5FU2 Regimen): A Clinical Dose-Finding and Pharmacokinetic Study in Patients With Pretreated Metastatic Colorectal Cancer J. Clin. Oncol., September 1, 1999; 17(9): 2901 - 2901. [Abstract] [Full Text] [PDF]

				U. Vanhoefer, A. Harstrick, C.-H. Kohne, W. Achterrath, Y. M. Rustum, S. Seeber, and H. Wilke Phase I Study of a Weekly Schedule of Irinotecan, High-Dose Leucovorin, and Infusional Fluorouracil as First-Line Chemotherapy in Patients With Advanced Colorectal Cancer J. Clin. Oncol., March 1, 1999; 17(3): 907 - 907. [Abstract] [Full Text] [PDF]

				J. A. Skirvin and V. Relias Review : Topoisomerase I inhibitors: 2. Irinotecan Journal of Oncology Pharmacy Practice, June 1, 1998; 4(2): 103 - 116. [Abstract] [PDF]

				L. B. Saltz Clinical Use of Irinotecan:Current Status and Future Considerations Oncologist, December 1, 1997; 2(6): 402 - 409. [Abstract] [Full Text] [PDF]

				J. G. Slatter, P. Su, J. P. Sams, L. J. Schaaf, and L. C. Wienkers Bioactivation of the Anticancer Agent CPT-11 to SN-38 by Human Hepatic Microsomal Carboxylesterases and the in Vitro Assessment of Potential Drug Interactions Drug Metab. Dispos., October 1, 1997; 25(10): 1157 - 1164. [Abstract] [Full Text]